Chapter 041

Immunotherapy

John A. Yagiela and Anahid Jewett1

CITED REFERENCES

  1. Abou-Jawde R, Choueiri T, Alemany C, et al: An overview of targeted treatments in cancer. Clin Ther 25:2122-2137, 2003. PUBMED Abstract
  2. Akiyama K, Yokota K, Kagawa S, et al: cDNA cloning and interferon γ down-regulation of proteasomal subunits X and Y. Science 265:1231-1234, 1994. PUBMED Abstract
  3. Bach JF, Bach MA, Charreire J, et al: The mode of action of thymic hormones. Ann N Y Acad Sci 332:23-32, 1979. PUBMED Abstract
  4. Baiocchi RA, Caligiuri MA: Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci U S A 91:5577-5581, 1994. PUBMED Abstract
  5. Baskar S, Ostrand-Rosenberg S, Nabavi N, et al: Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A 90:5687-5690, 1993. PUBMED Abstract
  6. Benenson AS, editor: Control of communicable diseases manual: an official report of the American Public Health Association, ed 16, Washington, DC, 1995, American Public Health Association.
  7. Boise LH, Thompson CB: Hierarchical control of lymphocyte survival. Science 274:67-68, 1996. PUBMED Abstract
  8. Childers NK, Zhang SS, Michalek SM: Oral immunization of humans with dehydrated liposomes containing Streptococcus mutans glucosyltransferase induces salivary immunoglobulin A2 antibody responses. Oral Microbiol Immunol 9:146-153, 1994. PUBMED Abstract
  9. Choi J, Chen J, Schreiber SL, et al: Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP, Science 273:239-242, 1996. PUBMED Abstract
  10. Cronstein BN: Second-line antirheumatic drugs. In Gallin JI, Snyderman R, editors: Inflammation: basic principles and clinical correlates, ed 3, Philadelphia, 1999, Lippincott Williams & Wilkins.
  11. de Camargo PM: Cyclosporin- and nifedipine-induced gingival enlargement: an overview. J West Soc Periodontol 37:57-64, 1989. PUBMED Abstract
  12. Dinarello CA: Interleukin-1: a proinflammatory cytokine. In Gallin JI, Snyderman R, editors: Inflammation: basic principles and clinical correlates, ed 3, Philadelphia, 1999, Lippincott Williams & Wilkins.
  13. Dinarello CA: Modalities for reducing interleukin 1 activity in disease. Immunol Today 14:260-264, 1993. PUBMED Abstract
  14. Drug facts and comparisons, 2004, ed 58, St Louis, 2003, Facts and Comparisons.
  15. Eisen D, Ellis CN, Duell EA, et al: Effect of topical cyclosporine rinse on oral lichen planus: a double-blind analysis. N Engl J Med 323:290-294, 1990. PUBMED Abstract
  16. Ferrone S, Dierich MP, editors: Handbook of monoclonal antibodies: applications in biology and medicine, Park Ridge, NJ, 1985, Noyes.
  17. Goldstein AL, Low TL, McAdoo M, et al: Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A 74:725-729, 1977. PUBMED Abstract
  18. Hassell TM, Hefti AF: Drug-induced gingival overgrowth: old problem, new problem. Crit Rev Oral Biol Med 2:103-137, 1991. PUBMED Abstract
  19. Horning SJ: Future directions in radioimmunotherapy for B-cell lymphoma. Semin Oncol 30(suppl 17):29-34, 2003. PUBMED Abstract
  20. Hsu DH, de Waal Malefyt R, Fiorentino DF, et al: Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 250:830-832, 1990. PUBMED Abstract
  21. Jackson S, Mestecky J, Childers NK, et al: Liposomes containing anti-idiotypic antibodies: an oral vaccine to induce protective secretory immune responses specific for pathogens of mucosal surfaces. Infect Immun 58:1932-1936, 1990. PUBMED Abstract
  22. Kiechle FL, Zhang X: Apoptosis: biochemical aspects and clinical implications. Clin Chim Acta 326:27-45, 2002. PUBMED Abstract
  23. LeBlanc AC: Natural cellular inhibitors of caspases. Prog Neuropsychopharmacol Biol Psychiatr 27:215-229, 2003. PUBMED Abstract
  24. Lehner T, Mehlert A, Caldwell J: Local active gingival immunization by a 3,800-molecular-weight streptococcal antigen in protection against dental caries. Infect Immun 52:682-687, 1986. PUBMED Abstract
  25. Lehner T, Wilton JMA, Ivanyi L: Double blind crossover trial of levamisole in recurrent aphthous ulceration. Lancet 2:926-929, 1976. PUBMED Abstract
  26. Liu C-C, Walsh CM, Young JD-E: Perforin: structure and function. Immunol Today 16:194-201, 1995. PUBMED Abstract
  27. Liu J, Farmer JD, Jr, Lane WS, et al: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807-815, 1991. PUBMED Abstract
  28. McHugh SM, Deighton J, Stewart AG, et al: Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 25:828-838, 1995. PUBMED Abstract
  29. Michalek SM, Childers NK: Development and outlook for a caries vaccine. Crit Rev Oral Biol Med 1:37-54, 1990. PUBMED Abstract
  30. Michel G, Kemeny L, Homey B, et al: FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol Today 17:106-108, 1996. PUBMED Abstract
  31. Mitsiades CS, Poulaki V, Mitsiades N: The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer. J Endocrinol 178:205-216, 2003. PUBMED Abstract
  32. Powrie F, Coffman RL: Cytokine regulation of T-cell function: potential for therapeutic intervention. Trends Pharmacol Sci 14:164-168, 1993. PUBMED Abstract
  33. Scheinman RI, Cogswell PC, Lofquist AK, et al: Role of transcriptional activation of I-κβα in mediation of immunosuppression by glucocorticoids. Science 270:283-290, 1995. PUBMED Abstract
  34. Schiff RI, Rudd C, Johnson R, et al: Use of a chemically modified intravenous IgG preparation in severe primary humoral immunodeficiency: clinical efficacy and attempts to individualize dosage. Clin Immunol Immunopathol 31:13-23, 1984. PUBMED Abstract
  35. Shankaran V, Schreiber RD: The interferons: basic biology and therapeutic potential. In Austen KF, Burakoff SJ, Rosen FS, et al, editors: Therapeutic immunology, ed 2, Cambridge, MA, 2001, Blackwell Science.
  36. Shuai K, Schindler C, Prezioso VR, et al: Activation of transcription of IFN-γ: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 258:1808-1812, 1992. PUBMED Abstract
  37. Smith DJ, Taubman MA, Holmberg CF, et al: Antigenicity and immunogenicity of a synthetic peptide derived from a glucan-binding domain of mutans streptococcal glucosyltransferase. Infect Immun 61:2899-2905, 1993. PUBMED Abstract
  38. Smith DJ, Taubman MA, King WF, et al: Immunological characteristics of a synthetic peptide associated with a catalytic domain of mutans streptococcal glucosyltransferase. Infect Immun 62:5470-5476, 1994. PUBMED Abstract
  39. Smith KA: Interleukin-2 immunostimulation. In Austen KF, Burakoff SJ, Rosen FS, et al, editors: Therapeutic immunology, ed 2, Cambridge, MA, 2001, Blackwell Science.
  40. Taniguchi T, Minami Y: The IL-2/IL-2 receptor system: a current overview. Cell 73:5-8, 1993. PUBMED Abstract
  41. The IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661, 1993. PUBMED Abstract
  42. Viola A, Lanzavecchia A: T cell activation determined by T cell receptor number and tunable thresholds. Science 273:104-106, 1996. PUBMED Abstract
  43. Waldmann TA: The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 14:264-270, 1993. PUBMED Abstract
  44. Winter G, Harris WJ: Humanized antibodies. Immunol Today 14:243-246, 1993. PUBMED Abstract

GENERAL REFERENCES

  1. Abbas AK, Lichtman AH: Basic immunology: functions and disorders of the immune system, Philadelphia, 2001, Saunders.
  2. Alberts B, Johnson A, Lewis J, et al: Molecular biology of the cell, ed 5, New York, 2008, Garland.
  3. Apostolopoulos V, Yuriev E, Lazoura E, et al: MHC and MHC-like molecules: structural perspectives on the design of molecular vaccines, Hum Vaccin 4:400-409, 2008. PUBMED Abstract
  4. Austen KF, Burakoff SJ, Rosen FS, et al, editors: Therapeutic immunology, ed 2, Cambridge, MA, 2001, Blackwell Science.
  5. Feldmann M: Many cytokines are very useful therapeutic targets in disease, J Clin Invest 118:3533-3536, 2008. PUBMED Abstract
  6. Gallin JI, Snyderman R, editors: Inflammation: basic principles and clinical correlates, ed 3, Philadelphia, 1999, Lippincott Williams & Wilkins.
  7. Gray D, Siepmann K, van Essen D, et al: B-T lymphocyte interactions in the generation and survival of memory cells, Immunol Rev 150:45-61, 1996. PUBMED Abstract
  8. Guy CS, Vignali DA: Organization of proximal signal initiation at the TCR:CD3 complex, Immunol Rev 232:7-21, 2009. PUBMED Abstract
  9. Janeway C Jr, Travers P: Immunobiology—the immune system in health and disease, ed 6, London, 2005, Garland.
  10. Jenkins MR, La Gruta NL, Doherty PC, et al: Visualizing CTL activity for different CD8+ effector T cells supports the idea that lower TCR/epitope avidity may be advantageous for target cell killing, Cell Death Differ 16:537-542, 2009. PUBMED Abstract
  11. Kindt TJ, Goldsby RA, Osborne BA, et al, editors: Kuby immunology, 2007, Freeman.
  12. Loke P, Allison JP: Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells, Arthritis Res Ther 6:208-214, 2004. PUBMED Abstract
  13. Melzer N, Meuth SG, Wiendl H: CD8+ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability, FASEB J 23:3659-3673, 2009. PUBMED Abstract
  14. Nitta T, Murata S, Ueno T, et al: Thymic microenvironments for T-cell repertoire formation, Adv Immunol 99:59-94, 2008. PUBMED Abstract
  15. Rich RR, Fleisher TA, Shearer WT, et al, editors: Clinical immunology: principles and practice, ed 32, London, 2001, Mosby International.
  16. Stavnezer, J, Guikema JE, Schrader CE: Mechanism and regulation of class switch recombination, Annu Rev Immunol 26:261-292, 2008. PUBMED Abstract
  17. Turner SJ, La Gruta NL, Kedzierska K, et al: Functional implications of T cell receptor diversity, Curr Opin Immunol 21:286-290, 2009. PUBMED Abstract
  18. von Boehmer H, Melchers F: Checkpoints in lymphocyte development and autoimmune disease, Nat Immunol 11:14-20, 2010. PUBMED Abstract

1The authors wish to recognize Dr. Kenneth T. Miyasaki for his past contributions to this chapter.